-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Assumes Protagonist Therapeutics at Outperform, Raises Price Target to $190

Benzinga·10/12/2026 12:53:47
語音播報
Leerink Partners analyst Will Soghikian assumes Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform rating and raises Price Target to $190.